U
Ulf Tidefelt
Researcher at Örebro University
Publications - 48
Citations - 2707
Ulf Tidefelt is an academic researcher from Örebro University. The author has contributed to research in topics: Daunorubicin & Cytarabine. The author has an hindex of 23, co-authored 48 publications receiving 2472 citations.
Papers
More filters
Journal ArticleDOI
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson,Petar Antunovic,Åsa Rangert Derolf,Sören Lehmann,Lars Möllgård,Dick Stockelberg,Ulf Tidefelt,Anders Wahlin,Martin Höglund +8 more
TL;DR: Standard intensive treatment improves early death rates and long-term survival compared with palliation and most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction.
Journal ArticleDOI
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Sören Lehmann,Vladimir J.N. Bykov,Dina Ali,Ove Andrén,Honar Cherif,Ulf Tidefelt,Bertil Uggla,Jeffrey Yachnin,Gunnar Juliusson,Ali Moshfegh,Christer Paul,Klas G. Wiman,Per-Ola Andersson +12 more
TL;DR: It is concluded that APR-246 is safe at predicted therapeutic plasma levels, shows a favorable pharmacokinetic profile, and can induce p53-dependent biologic effects in tumor cells in vivo.
Journal ArticleDOI
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
Sebastian Lehmann,A. Ravn,L. Carlsson,Petar Antunovic,Stefan Deneberg,Lars Möllgård,A. Rangert Derolf,Dick Stockelberg,Ulf Tidefelt,Anders Wahlin,Lovisa Wennström,Martin Höglund,Gunnar Juliusson +12 more
TL;DR: It is concluded that ED rates remain very high in an unselected APL population in the population-based Swedish Adult Acute Leukemia Registry, and female sex predominated among younger APL patients.
Journal Article
Expression of Glutathione Transferase π as a Predictor for Treatment Results at Different Stages of Acute Nonlymphoblastic Leukemia
Ulf Tidefelt,Annika Elmhorn-Rosenborg,Christer Paul,Xiao-Yong Hao,Bengt Mannervik,Lennart Eriksson +5 more
TL;DR: There was a significant correlation between the expression of GST pi at the time of diagnosis and the subsequent treatment results and it is concluded that GST pi is a useful marker for clinical resistance to cytostatic drugs in acute nonlymphoblastic leukemia.
Journal ArticleDOI
P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia
Ulf Tidefelt,Jan Liliemark,Astrid Gruber,Eva Liliemark,Britt Sundman-Engberg,Gunnar Juliusson,Leif Stenke,Annika Elmhorn-Rosenborg,L. Möllgård,S. Lehman,Dawei Xu,A. Covelli,Bengt Gustavsson,Christer Paul +13 more
TL;DR: Results strongly suggest that valspodar, by interacting with Pgp, can increase the cellular uptake of dnr in leukemic blasts in vivo.